Clinical trial
A Multicenter, Prospective and Exploratory Study of Optical Coherence Tomography-Assisted Strategy for Interventional Management of Symptomatic Carotid Stenosis
NCT07886775 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started November 2026. Interventional study, 100 participants (estimated). Lead sponsor Beijing Tiantan Hospital; China. Primary measure: Any stroke or death from enrollment to 30 days after endovascular treatment of the qualifying artery...
How it compares
119 similar trials: same condition (Carotid Stenosis) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Prospective and Exploratory Study of Optical Coherence Tomography-Assisted Strategy for Interventional Management of Symptomatic Carotid Stenosis
- Lead sponsor
- Beijing Tiantan Hospital
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 1, 2026
- Completion date
- December 31, 2029
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- China
- Lead sponsor
- Beijing Tiantan Hospital
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| OCT guided endovascular treatment | Experimental | OCT guided endovascular treatment |
Show registry wordingAll the participants will undergo endovascular treatment guided by OCT. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Any stroke or death from enrollment to 30 days after endovascular treatment of the qualifying artery, or ipsilateral ischemic stroke or ischemic driven qualifying artery revascularization during the remaining follow-up period up to 6 months | 6 months |
Show registry wordingThis outcome includes ischemic/hemorrhagic stroke or all-cause death from enrollment to 30 days after endovascular treatment of the qualifying artery, or ipsilateral ischemic stroke or ischemic driven qualifying artery revascularization during the remaining follow-up period up to 6 months. | |
Lead sponsor's other trials
Beijing Tiantan Hospital, most recent start first.
+485 more trials
Similar trials
Same condition (Carotid Stenosis) and phase, most recent start first.
+114 more trials See the condition page